academic article

• TYK2 regulates tau levels, phosphorylation and aggregation in a tauopathy mouse model..  Nature Neuroscience.  27:2417-2429. 2024
• APOE2 gene therapy reduces amyloid deposition and improves markers of neuroinflammation and neurodegeneration in a mouse model of Alzheimer disease..  Molecular therapy : the journal of the American Society of Gene Therapy.  32:1373-1386. 2024
• Report of the APOE4 National Institute on Aging/Alzheimer Disease Sequencing Project Consortium Working Group: Reducing APOE4 in Carriers is a Therapeutic Goal for Alzheimer's Disease..  Annals of Neurology.  95:625-634. 2024
• Apolipoprotein E4 Reduction with Antisense Oligonucleotides Decreases Neurodegeneration in a Tauopathy Model..  Annals of neurology.  89:952-966. 2021
• Alzheimer disease.  Nature Reviews Disease Primers.  2021
• Alternatives to amyloid for Alzheimer's disease therapies-a symposium report..  Annals of the New York Academy of Sciences.  1475:3-14. 2020
• Targeting of nonlipidated, aggregated apoE with antibodies inhibits amyloid accumulation..  The Journal of clinical investigation.  128:2144-2155. 2018
• Alzheimer's Disease-Related Dementias Summit 2016: National research priorities..  Neurology.  89:2381-2391. 2017
• Anti-ApoE antibody given after plaque onset decreases Aβ accumulation and improves brain function in a mouse model of Aβ amyloidosis..  The Journal of neuroscience : the official journal of the Society for Neuroscience.  34:7281-92. 2014
• Apolipoprotein E4 effects in Alzheimer's disease are mediated by synaptotoxic oligomeric amyloid-β..  Brain : a journal of neurology.  135:2155-68. 2012
• Rapid appearance and local toxicity of amyloid-beta plaques in a mouse model of Alzheimer's disease..  Nature.  451:720-4. 2008
• National Institute of Neurological Disorders and Stroke-Canadian Stroke Network vascular cognitive impairment harmonization standards..  Stroke.  37:2220-41. 2006